Internal Medicine, Hematology & Oncology · Lake Worth, FL
NPI
1043428089
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3450 Lantana Rd, Ste 100
Lake Worth, FL, 33462
Phone (561) 965-1864
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
74,622 services
Medicare patients, 2024
278
Average age 73
Drug cost, 2024
$4.0M
1,444 prescriptions
Company payments, 2025
$8,814
From 47 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Seetal Mewar was code J1439 (injection, ferric carboxymaltose, 1 mg), 37,500 times for 17 patients. In total Seetal Mewar billed 74,622 services in 108 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-11-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 37,500 | 17 | $0.87 | $33K |
| 85025 Blood Count | Office | 517 | 166 | $7.58 | $3,919 |
| 36415 Venipuncture Blood Collection | Office | 463 | 162 | $8.65 | $4,005 |
| 80053 Clinical Chemistry | Office | 345 | 131 | $10.35 | $3,571 |
| 99214 Office E&M - Established | Office | 278 | 125 | $97.53 | $27K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 228 | 49 | $0.51 | $117 |
| 96401 Chemotherapy Administration | Office | 141 | 16 | $58.10 | $8,192 |
| 96365 Intravenous Infusion, Hydration | Office | 127 | 36 | $50.96 | $6,472 |
| 84466 Clinical Chemistry | Office | 125 | 60 | $12.50 | $1,563 |
| 82728 Clinical Chemistry | Office | 125 | 64 | $13.36 | $1,670 |
| 83540 Clinical Chemistry | Office | 125 | 60 | $6.34 | $793 |
| 99223 Hospital E&M - Initial | Facility | 117 | 103 | $140.23 | $16K |
| 99233 Hospital E&M - Subsequent | Facility | 106 | 52 | $98.18 | $10K |
| 99215 Office E&M - Established | Office | 80 | 55 | $142.35 | $11K |
| 96367 Intravenous Infusion, Hydration | Office | 73 | 17 | $23.05 | $1,683 |
By year: 2022 $901K for 66,315 services; 2023 $641K for 51,218 services; 2024 $1.1M for 74,622 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 517 | 166 | $7.58 | $3,919 |
| 36415 Venipuncture Blood Collection | 463 | 162 | $8.65 | $4,005 |
| 80053 Clinical Chemistry | 345 | 131 | $10.35 | $3,571 |
| 83540 Clinical Chemistry | 125 | 60 | $6.34 | $793 |
| 84466 Clinical Chemistry | 125 | 60 | $12.50 | $1,563 |
| 82728 Clinical Chemistry | 125 | 64 | $13.36 | $1,670 |
| 82607 Clinical Chemistry | 48 | 44 | $14.78 | $709 |
| 82746 Clinical Chemistry | 41 | 38 | $14.41 | $591 |
| 85044 Blood Count | 40 | 28 | $4.22 | $169 |
| 83615 Clinical Chemistry | 38 | 35 | $5.92 | $225 |
Medicare prescription drug claims, 2024
In 2024, the drug Seetal Mewar prescribed most often to Medicare patients was Eliquis (Apixaban), with 142 prescriptions and refills. In total Seetal Mewar wrote 1,444 Medicare prescriptions that cost $4.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 142 | 181 | 38 | $105K |
| Letrozole Generic | 85 | 225 | 28 | $2,713 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 83 | 83 | 30 | $2,779 |
| Hydroxyurea Generic | 68 | 170 | 23 | $2,624 |
| Anastrozole Generic | 61 | 154 | 19 | $942 |
| Gabapentin Generic | 55 | 95 | 19 | $490 |
| Dexamethasone Generic | 51 | 53 | 24 | $815 |
| Revlimid Lenalidomide | 42 | 42 | Under 11 | $761K |
| Ondansetron Hcl Generic | 31 | 33 | 19 | $693 |
| Tamoxifen Citrate Generic | 31 | 71 | Under 11 | $676 |
| Tramadol Hcl Generic | 29 | 29 | 15 | $216 |
| Exemestane Generic | 27 | 65 | Under 11 | $5,193 |
| Prednisone Generic | 25 | 31 | 12 | $112 |
| Temazepam Generic | 23 | 31 | Under 11 | $221 |
| Jakafi Ruxolitinib Phosphate | 23 | 23 | Under 11 | $381K |
Brand drugs: 414 claims; generic drugs: 1,030 claims; opioid claims: 156.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Seetal Mewar $8,814 ($8,814 in general payments such as food, travel and fees) from 47 companies. The largest payer was Shorla Oncology Inc. with $3,850.
| Company | Payments | Amount |
|---|---|---|
| Shorla Oncology Inc. | 1 | $3,850 |
| Novartis Pharmaceuticals Corporation NVS | 18 | $1,125 |
| Genzyme Corporation SNY | 13 | $313 |
| Merck Sharp & Dohme LLC MRK | 12 | $276 |
| Pfizer Inc. PFE | 17 | $251 |
| Janssen Biotech, Inc. JNJ | 15 | $222 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 9 | $207 |
| Daiichi Sankyo Inc. 4568.T | 9 | $193 |
| Genentech USA, Inc. ROG.SW | 6 | $177 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.